Cytokinetics (CYTK) PT Lowered to $55 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.31 --0%
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
JPMorgan analyst Tessa Romero lowered the price target on Cytokinetics (NASDAQ: CYTK) to $55.00 (from $64.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Cytokinetics to Participate in November Investor Conferences
- PT Telekomunikasi Indonesia Tbk (TLKM:IJ) (TLKMF) PT Lowered to IDR2,200 at Macquarie
- EnPro Industries (NPO) PT Raised to $440 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
